deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00720941

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ)

Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Sponsor: Novartis Pharmaceuticals

Conditions Carcinoma, Renal Cell
Interventions Pazopanib Sunitinib
Updated 17 times since 2017 Last updated: Mar 12, 2025 Started: Aug 14, 2008 Primary completion: May 21, 2012 Completion: Mar 24, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00720941, this PHASE3 trial focuses on Carcinoma, Renal Cell and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 17 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2019 · 13 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  3. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2018 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Aug 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Alkmaar, Netherlands , Amsterdam, Netherlands , Annapolis, United States , Arezzo, Italy , Arlington, United States , Atlanta, United States , Badalona, Spain , Barakaldo (Vizcaya), Spain , Barcelona, Spain and 180 more locations